SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is trending as investors anticipate upcoming earnings, with some speculating about a potential leak and others pointing to favorable macroeconomic conditions like potential rate cuts. The community is weighing the possibility of a post-earnings short squeeze against concerns of overvaluation and a potential sell-off. Some see SOFI as a long-term growth play, drawing comparisons to other high-growth tech companies and anticipating future S&P 500 inclusion.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital ($GLXY) is trending due to a recently announced $1 billion convertible note offering, leading to community debate about potential dilution and the company's growth strategy. Some investors view the offering as a strategic move to fund data center expansion and capitalize on AI opportunities, while others express concern over the impact on existing shareholders. Community members are actively discussing the implications of the offering, potential ERCOT approval, and comparing GLXY to other stocks in the crypto and AI sectors.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZ is trending as community members discuss the company's recent decision to enact a reverse stock split. Some investors view this as a strategic move to attract institutional investors and increase the stock price, while others worry about potential dilution and question the company's management. Discussions also involve ETHZ's relationship to Ethereum's price movements and comparisons to other crypto-related stocks.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following Rosenblatt's bullish report highlighting a major AI data center deal, positioning the company to challenge competitors in the AI infrastructure space. Community members are debating the significance of this move, with some questioning the hype and others pointing to Qualcomm's attractive valuation compared to peers. Option volume is elevated, suggesting increased investor interest.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies ($AVR) is trending following the enrollment of the first patients in its global pivotal trial for the DurAVR Transcatheter Heart Valve, with the procedures performed in Denmark. Community members are discussing the company's potential, recent stock offerings, and potential price targets. Some traders are also pointing to technical indicators like cup and handle patterns while others mention institutional support.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the impact of restructuring and potential dividend cuts ahead of earnings. The community is actively discussing insider sentiment, with some questioning the company's leadership and others seeing a long-term value play due to its high dividend yield. Broader market concerns and upcoming earnings are fueling uncertainty around the stock's near-term direction.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X (DGXX) is trending due to significant volume and community excitement around its potential in the AI infrastructure space, particularly its partnership with Super Micro Computer (SMCI) and expansion of data center capacity. Investors are drawn to DGXX's positioning in the growing AI infrastructure market and its measurable milestones, leading to discussions about potential market cap and future growth. Some members mention the potential for a buyout, while others are bullish based on the company's financial position.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors anticipate the upcoming earnings report, focusing on potential margin improvements and guidance for 2026. Community discussions revolve around the impact of rising costs, government regulations, and Optum's performance, while some traders are closely monitoring technical indicators and analyst ratings.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending due to a significant stock drop following a paused trial of its gene therapy nex-z after a patient experienced liver issues, sparking discussions around the severity and implications for the company's pipeline. The community is debating whether this is an overreaction and a buying opportunity, or a sign of deeper problems with the therapy, while analysts are adjusting price targets but largely maintaining buy ratings. Some traders anticipate a potential short squeeze given the high short interest and the company's cash reserves.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as the community discusses its recent price action and potential. Conversations revolve around adding on dips and speculation about future price targets, with some comparing its potential to past crypto successes. The discussions also highlight the project's focus on AI agents and their growing ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail buzz around NRx Pharmaceuticals picked up Monday after the company said that the U.S. Food and Drug Administration (FDA) granted fast-track designation to its NRX-100 therapy for treating suicidal thoughts in patients with depression, including bipolar depression.The new designation means NRX-100 could be used to treat about 13 million Americans who consider suicide each year, which is 10x more than under its 2017 designation, which covered only bipolar depression when combined with NRX-101.However,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals’ stock</a> closed down 7.9% at $0.2 on Monday, then inched up 0.2% in after-hours trading.The FDA determined NRX-100 has the potential to address an unmet medical need, making the drug eligible for the Commissioner’s National Priority Voucher (CNPV) program and the agency’s Accelerated Approval pathway.&nbsp;NRx said it has applied for a CNPV, which could shorten the review cycle.The company cited multiple controlled trials submitted to the FDA that showed clinically meaningful reductions in suicidal ideation with intravenous ketamine. In a Columbia University study licensed by NRx, 55% of patients met the response criteria compared with 30% for an active comparator.&nbsp;In a French government-sponsored study also licensed by NRx, 63% of participants achieved remission within three days, compared to 31% for the placebo group.CEO Jonathan Javitt said the designation was a “significant step forward” in addressing suicide risk among soldiers, veterans, first responders, and civilians. NRx plans to post an expanded access policy for NRX-100 within two weeks and will meet with the FDA to finalize the data package for its Accelerated Approval and CNPV application.The company noted&nbsp;that NRX-100 is the first preservative-free ketamine presentation filed with the FDA. Current ketamine products often contain benzethonium chloride, a preservative not recognized as safe by the FDA.&nbsp;NRx has petitioned the FDA to ban the compound from all intravenous ketamine products and has started producing sterile, preservative-free ketamine in the U.S.Roughly 13 million U.S. adults seriously think about suicide each year, with 1.5 million attempts and one life lost every 11 minutes, the company said in a statement, citing the CDC.NRx pointed out that while the Department of Veterans Affairs and the Department of Defense cover intravenous ketamine, most insurers won’t pay for it as it’s only officially approved as an anesthetic.The fast-track designation provides drugmakers with closer contact with the FDA, the opportunity to qualify for Priority Review and Accelerated Approval if certain requirements are met, and the option to submit parts of an application for review as they are completed.On Stocktwits, retail sentiment for NRx Pharmaceuticals was ‘extremely bullish’ late Monday amid ‘extremely high’ message volume.NRx Pharmaceuticals’ stock has risen 5.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail buzz around NRx Pharmaceuticals (NRXP) picked up Monday after the company said that the U.S. Food and Drug Administration (FDA) granted fast-track designation to its NRX-100 therapy. (Photo credit: Getty Images)

Why Small-Cap Biotech NRx Pharmaceuticals Is Drawing Heavy Retail Buzz 

NRx said the FDA’s fast-track status makes NRX-100 eligible for the Commissioner’s National Priority Voucher program and the FDA’s Accelerated Approval pathway, and the company has already applied for a CNPV.

Equity

NRx Pharmaceuticals Inc. (NRXP) (+900% Weekly Message Volume)The Wilmington, Delaware-based pharma company garnered retail attention after the FDA granted it a $4.3 million filing fee waiver for its New Drug Application (NDA) for NRX-100, a preservative-free ketamine treatment for depression.&nbsp;The company aims to file the NDA using existing resources by the end of Q2. If approved, the drug could gain long-term exclusivity.&nbsp;NRx plans to submit data showing NRX-100 is superior to placebo, an active comparator, and potentially even electroshock therapy for treatment-resistant depression and suicidal ideation.<a href="https://stocktwits.com/symbol/NRXP">NRx stock</a> has fallen over 2.8% this year.CVS Health Corp. (CVS) (+650% Weekly Message Volume)The health solutions giant&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cvs-reports-upbeat-q1-earnings-raises-full-year-guidance/chLv3eARbit">posted</a> strong first-quarter results, with all three divisions (healthcare benefits, health services, and pharmacy) beating Wall Street expectations.&nbsp;Retail buzz also intensified after its pharmacy benefits unit struck a deal to make Wegovy more accessible to members, replacing Zepbound as the preferred drug — a move expected to save health plans up to 15% on annual costs.&nbsp;Stocktwits chatter was also fueled by a DOJ lawsuit against Aetna and other insurers, accusing them and major broker firms of paying illegal kickbacks for Medicare Advantage enrollments between 2016 and 2021.<a href="https://stocktwits.com/symbol/CVS">CVS stock</a> has gained nearly 50% this year.&nbsp;ReShape Lifesciences Inc. (RSLS) (+600% Weekly Message Volume)ReShape Lifesciences gained attention with new preclinical data on its Diabetes Neuromodulation&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rsls-stock-soars-on-us-patent-for-diabetes-neuromodulation-system/chQSOp9RbQM">device</a>, showing promising results in stabilizing glucose and glucagon levels in Type 1 diabetic swine without affecting heart rate.&nbsp;Investors also reacted to news that the company received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering its swallowable intragastric balloon system. This patent could potentially protect the technology until at least January 2031.<a href="https://stocktwits.com/symbol/RSLS">ReShape shares</a> have tumbled over 90% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wilmington, Delaware-based NRx Pharmaceuticals registered the biggest spike in retail message volume among healthcare stocks last week.  | Image source: Getty Images

Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter

Favorable regulatory moves for a new drug application, blowout earnings and promising preclinical data triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.  

Favorable regulatory moves for a new drug application, blowout earnings and promising preclinical data triggered a flurry of discussions on Stocktwits for these tickers for the week ended May 2, 2025.  

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and...

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial...

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition HOPE Therapeutics, Inc. and NRx Pharmaceuticals...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt NRx Pharmaceuticals, Inc...

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of...

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel HOPE...

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

NRX Pharmaceuticals Inc

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$3.14
Prev Close	$3.15
Open	$3.22
Dividend Yield	0.00%
50-Day Moving Average	$2.97
Beta	0.90
Avg. Volume	460,005.76
PE Ratio	-1.41

52-Week High	$6.01
52-Week Low	$1.12
Market Capitalization	$74.88M
EPS (Annual)	-$2.36
Price to Book	-1.72
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

NRXP
NRX Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NRXP News

NRXPNRX Pharmaceuticals Inc